Vivos converts $2.86M debt into 11.4M shares; dilution up to 52% of prior outstanding

Vivos Therapeutics, Inc.

Twelve exchange agreements with Streeterville Capital dated Aug 31, 2026 convert $2,861,270 of note principal into up to 11,445,080 shares at avg $0.25/share.
After exchanges, Streeterville Note balance reduced to ~$3.7M from original $8.225M (June 9, 2025).
Pre-exchange shares 22,164,313; post-settlement 33,609,393, a ~52% increase from dilution.
No cash proceeds; Section 3(a)(9) exemption; shares free-trading with tacked holding period to Jun 9, 2025.
Beneficial ownership limited to 4.9%; later exchanges require sell-down of prior shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.